|
|
This article was retracted on June 11, 2009.
Blood, 15 February 2008, Vol. 111, No. 4, pp. 1805-1810.
Prepublished online as a Blood First Edition Paper on November 8, 2007September 17, 2007; DOI 10.1182/blood-2007-07-101212.
 Previous Article | Next Article 
Submitted July 16, 2007
Accepted September 13, 2007
Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial
Abderrahman Abdelkefi*, Lamia Torjman, Tarek Ben Othman, Saloua Ladeb, Amel Lakhal, Neila Ben Romdhane, Halima El Omri, Moez Elloumi, Hatem Belaaj, Ramzi Jeddi, Lamia Aissaoui, Habib Ksouri, Assia Ben Hassen, Fahmi Msadek, Ali Saad, Mohamed Hsairi, Kamel Boukef, Ahlem Amouri, Hechmi Louzir, Koussay Dellagi, and Abdeladhim Ben Abdeladhim
Department of Hematology, Centre National de Greffe de Moelle Osseuse, Tunis, Tunisia
Department of Hematology, Hopital La Rabta, Tunis, Tunisia
Department of Hematology, Hopital Farhat Hached, Sousse, Tunisia
Department of Hematology, Hopital Hedi Chaker, Sfax, Tunisia
Department of Hematology, Hopital Aziza Othmana, Tunis, Tunisia
Department of Immunology, Centre National de Greffe de Moelle Osseuse, Tunis, Tunisia
Department of Hematology, Hopital militaire, Tunis, Tunisia
Department of Cytogenetics, Hopital Farhat Hached, Sousse, Tunisia
Department of Statistics, Institut National de la Sante Publique, Tunis, Tunisia
Department of Hematology, Centre National de Transfusion Sanguine, Tunis, Tunisia
Department of Cytogenetics, Institut Pasteur de Tunis, Tunis, Tunisia
Department of Immunology, Institut Pasteur de Tunis, Tunis, Tunisia
* Corresponding author; email: aabdelkefi{at}yahoo.fr.
From April 2003 to December 2006, 195 patients with de novo symptomatic myeloma and less than 60 years of age, were randomly assigned to receive either tandem transplantation up-front [Arm A, n=97] or one autologous stem cell transplantation followed by a maintenance therapy with thalidomide (day +90, 100 mg per day during 6 months) [Arm B, n=98]. Patients included in arm B received a second transplant at disease progression. In both arms, autologous stem cell transplantation was preceded by first-line therapy with thalidomide-dexamethasone and subsequent collection of peripheral blood stem cells with high-dose cyclophosphamide (4 g/m2) and granulocyte colony stimulating factor. Data were analyzed on an intent-to-treat basis. With a median follow-up of 33 months (range, 6-46 months), the 3-year overall survival was 63% in arm A, and 88% in arm B (P= .05). The 3-year progression-free survival was 57% in arm A, and 85% in arm B (P= .03). Up-front single autologous transplant followed by 6 months of maintenance therapy with thalidomide (with second transplant in reserve for relapse or progression) is an effective therapeutic strategy to treat multiple myeloma patients, and appears superior to tandem transplant in this setting. This study was registered at http://clinicaltrails.gov as (NCT 00207805).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Is tandem autotransplantation necessary in myeloma?
- Sundar Jagannath
Blood 2008 111: 1751-1752.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. Cavo, L. Pantani, P. Tacchetti, M. C. Pallotti, A. Brioli, A. Petrucci, E. Zamagni, and P. Tosi
Thalidomide Maintenance in Multiple Myeloma: Certainties and Controversies
J. Clin. Oncol.,
November 10, 2009;
27(32):
e186 - e187.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mehta
Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
J Natl Cancer Inst,
October 21, 2009;
101(20):
1430 - 1431.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kumar, M. Kharfan-Dabaja, and B. Djulbegovic
Response: Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
J Natl Cancer Inst,
October 21, 2009;
101(20):
1431 - 1433.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cavo, F. Di Raimondo, E. Zamagni, F. Patriarca, P. Tacchetti, A. F. Casulli, S. Volpe, G. Perrone, A. Ledda, M. Ceccolini, et al.
Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma
J. Clin. Oncol.,
October 20, 2009;
27(30):
5001 - 5007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Kristen, F.-U. Sack, S. O. Schonland, U. Hegenbart, B. M. Helmke, A. Koch, P. A. Schnabel, C. Rocken, S. Hardt, A. Remppis, et al.
Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis
Eur J Heart Fail,
October 1, 2009;
11(10):
1014 - 1020.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K Kettle, K. L Finkbiner, S. E Klenke, R. D Baker, D. W Henry, and C. B Williams
Initial therapy in multiple myeloma: investigating the new treatment paradigm
Journal of Oncology Pharmacy Practice,
September 1, 2009;
15(3):
131 - 141.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Kumar, S. Giralt, E. A. Stadtmauer, J. L. Harousseau, A. Palumbo, W. Bensinger, R. L. Comenzo, S. Lentzsch, N. Munshi, R. Niesvizky, et al.
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
Blood,
August 27, 2009;
114(9):
1729 - 1735.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Hussein, V. Bolejack, J. A. Zonder, B. G.M. Durie, A. J. Jakubowiak, J. J. Crowley, and B. Barlogie
Phase II Study of Thalidomide Plus Dexamethasone Induction Followed by Tandem Melphalan-Based Autotransplantation and Thalidomide-Plus-Prednisone Maintenance for Untreated Multiple Myeloma: A Southwest Oncology Group Trial (S0204)
J. Clin. Oncol.,
July 20, 2009;
27(21):
3510 - 3517.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Giralt, D. H. Vesole, G. Somlo, A. Krishnan, E. Stadtmauer, P. Mccarthy, M. C. Pasquini;, and on behalf of the Blood and Marrow Transplant Clini
Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
J Natl Cancer Inst,
July 1, 2009;
101(13):
964 - 964.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kumar and B. Djulbegovic
Response: Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
J Natl Cancer Inst,
July 1, 2009;
101(13):
966 - 967.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Spencer, H. M. Prince, A. W. Roberts, I. W. Prosser, K. F. Bradstock, L. Coyle, D. S. Gill, N. Horvath, J. Reynolds, and N. Kennedy
Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure
J. Clin. Oncol.,
April 10, 2009;
27(11):
1788 - 1793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kumar, M. A. Kharfan-Dabaja, A. Glasmacher, and B. Djulbegovic
Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
J Natl Cancer Inst,
January 21, 2009;
101(2):
100 - 106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Reece, J.-L. Harousseau, and M. A. Gertz
Nontransplant Therapy of Myeloma, High-dose Therapy for Myeloma, and a Personalized Care Plan for Treatment of Myeloma
ASCO Educational Book,
January 1, 2009;
2009(1):
502 - 509.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri
Biology, treatment, and time
Blood,
October 15, 2008;
112(8):
2999 - 3000.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. San-Miguel, J.-L. Harousseau, D. Joshua, and K. C. Anderson
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
J. Clin. Oncol.,
June 1, 2008;
26(16):
2761 - 2766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Palumbo, T. Facon, P. Sonneveld, J. Blade, M. Offidani, F. Gay, P. Moreau, A. Waage, A. Spencer, H. Ludwig, et al.
Thalidomide for treatment of multiple myeloma: 10 years later
Blood,
April 15, 2008;
111(8):
3968 - 3977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mehta
One or two autografts for myeloma?
Blood,
April 1, 2008;
111(7):
3899 - 3900.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-L. Harousseau
Induction Therapy in Multiple Myeloma
Hematology,
January 1, 2008;
2008(1):
306 - 312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
